EUROPEAN JOURNAL OF PHARMACOLOGY, cilt.983, sa. 983, ss.1-11, 2024 (SCI-Expanded)
Acute kidney injury (AKI) is a severe medical condition that can lead to illness and death. A disintegrin and
metalloprotease (ADAM) protein family is a potential treatment target for AKI due to its involvement in
inflammation, growth, and differentiation. While ADAM10 and ADAM17 have been identified as significant
contributors to inflammation, it is unclear whether they play a critical role in AKI. In this study, we induced AKI
in male and female mice using lipopolysaccharide, a bacterial endotoxin that causes inflammation and oxidative
stress. The role of kaempferol, which is found in many natural products and known to have antioxidant and antiinflammatory activity in many pre-clinical studies, was investigated through ADAM10/17 enzymes in AKI. We
also investigated the efficacy of a selective synthetic inhibitor named GW280264X for ADAM10/17 inhibition in
AKI. Blood urea nitrogen and creatinine levels were measured in serum, while tumor necrosis factor-α, vascular
adhesion molecule, interleukin (IL)-1β, glucose regulatory protein-78, IL-10, nuclear factor κ-B, thiobarbituric
acid reactive substances, total thiol, ADAM10, and ADAM17 levels were measured in kidney tissue. We also
evaluated kidney tissue histologically using hematoxylin and eosin, periodic acid-schiff, and caspase-3 staining.
This research demonstrates that GW280264X and kaempferol reduces inflammation and oxidative stress, as
evidenced by biochemical and histopathological results in AKI through ADAM10/17 inhibition. These findings
suggest that inhibiting ADAM10/17 may be a promising therapeutic approach for treating acute kidney injury.